(KRTX) – Company Press Releases
-
PureTech Announces Annual Results for Year Ended December 31, 2023
-
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
-
Kuehn Law Encourages KAMN, SNCE, KRTX, and BATL Investors to Contact Law Firm
-
Kuehn Law Encourages SNCE, MGRC, VINE, and KRTX Investors to Contact Law Firm
-
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
-
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
-
PureTech Year End Update and Outlook for 2024
-
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
-
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
-
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
-
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
-
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
-
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
-
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
-
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
-
PureTech to Present at Two Upcoming Investor Conferences
-
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
-
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
-
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
-
PureTech Health plc – Half-Year Report
-
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
-
Karuna Therapeutics Announces Leadership Appointments
-
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
-
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
-
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
-
PureTech Announces Annual Results for Year Ended December 31, 2022
-
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
-
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
-
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
-
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
-
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
-
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
-
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
-
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
-
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
-
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
-
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
PureTech Provides End of Year Report on Key Progress
-
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
-
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
-
Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference
-
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
-
Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
Back to KRTX Stock Lookup
